1
|
A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma. Invest New Drugs 2021; 40:81-90. [PMID: 34417914 DOI: 10.1007/s10637-021-01164-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Accepted: 08/09/2021] [Indexed: 10/20/2022]
Abstract
Background RX-3117 is an oral small molecule antimetabolite, cyclopentyl pyrimidyl nucleoside that is activated by cancer cells over-expressing uridine cytidine kinase 2 (UCK2). Single agent RX-3117 demonstrated efficacy in a phase I trial in patients with metastatic (met) pancreatic adenocarcinoma (PC). RX-3117 plus nab-paclitaxel (nab-Pac) was evaluated as a first line treatment in met-PC cancer. Methods This was a multicenter open label phase I/II 2-stage study investigating the combination of RX3117 plus nab-Pac in the frontline treatment of patients with met-PC. The phase I portion comprised a dose de-escalation design with primary objectives of determining the safety, tolerability and recommended phase 2 dose (RP2D) of RX-3117 (orally 700, 600, or 500 mg/day for 5 consecutive days with 2 days off/week) plus nab-Pac (intravenous (IV) 125 mg/m2 once weekly) for 3 weeks with 1 week off per a 4-week cycle. The primary objective was to determine the antitumor efficacy. Results 46 patients were enrolled (22 male/24 female; median age 67; 91% Caucasian). The RP2D of RX-3117 plus nab-Pac was 700 mg/day. No dose-limiting toxicities were observed (DLTs). The overall response rate (ORR) was 23.1% and disease control rate (DCR) 74.4%. RX-3117 pharmacokinetics (PK) results were similar to previously reported monotherapy phase 1 trial. All patients experienced a treatment emergent adverse event (TEAE) with the most common diarrhea, nausea, and fatigue.10.9% of patients experienced a serious adverse event (SAE) related to the combination. Conclusion RX-3117 plus nab-Pac in newly diagnosed met-PC patients demonstrated tolerability, safety, and early treatment efficacy.
Collapse
|
2
|
Balboni B, El Hassouni B, Honeywell RJ, Sarkisjan D, Giovannetti E, Poore J, Heaton C, Peterson C, Benaim E, Lee YB, Kim DJ, Peters GJ. RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment. Expert Opin Investig Drugs 2019; 28:311-322. [PMID: 30879349 DOI: 10.1080/13543784.2019.1583742] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
INTRODUCTION RX-3117 is an oral, small molecule cytidine analog anticancer agent with an improved pharmacological profile relative to gemcitabine and other nucleoside analogs. The agent has excellent activity against various cancer cell lines and xenografts including gemcitabine-resistant variants and it has excellent oral bioavailability; it is not a substrate for the degradation enzyme cytidine deaminase. RX-3117 is being evaluated at a daily oral schedule of 700 mg (5 days/week for 3 weeks) which results in plasma levels in the micromolar range that have been shown to be cytotoxic to cancer cells. It has shown clinical activity in refractory bladder cancer and pancreatic cancer. Areas covered: The review provides an overview of the relevant market and describes the mechanism of action, main pharmacokinetic/pharmacodynamic features and clinical development of this investigational small molecule. Expert opinion: RX-3117 is selectively activated by uridine-cytidine kinase 2 (UCK2), which is expressed only in tumors and has a dual mechanism of action: DNA damage and inhibition of DNA methyltransferase 1 (DNMT1). Because of its tumor selective activation, novel mechanism of action, excellent oral bioavailability and candidate biomarkers for patient selection, RX-3117 has the potential to replace gemcitabine in the treatment of a spectrum of cancer types.
Collapse
Affiliation(s)
- Beatrice Balboni
- a Department of Medical Oncology , Amsterdam UMC, VU University Medical Center , Amsterdam , Netherlands
| | - Btissame El Hassouni
- a Department of Medical Oncology , Amsterdam UMC, VU University Medical Center , Amsterdam , Netherlands
| | - Richard J Honeywell
- a Department of Medical Oncology , Amsterdam UMC, VU University Medical Center , Amsterdam , Netherlands
| | - Dzjemma Sarkisjan
- a Department of Medical Oncology , Amsterdam UMC, VU University Medical Center , Amsterdam , Netherlands
| | - Elisa Giovannetti
- a Department of Medical Oncology , Amsterdam UMC, VU University Medical Center , Amsterdam , Netherlands.,b Cancer Pharmacology Lab , Pisa , Italy
| | - Julie Poore
- c Rexahn Pharmaceuticals, Inc , Rockville , MD , USA
| | - Callie Heaton
- c Rexahn Pharmaceuticals, Inc , Rockville , MD , USA
| | | | - Ely Benaim
- c Rexahn Pharmaceuticals, Inc , Rockville , MD , USA
| | - Young B Lee
- c Rexahn Pharmaceuticals, Inc , Rockville , MD , USA
| | - Deog J Kim
- c Rexahn Pharmaceuticals, Inc , Rockville , MD , USA
| | - Godefridus J Peters
- a Department of Medical Oncology , Amsterdam UMC, VU University Medical Center , Amsterdam , Netherlands
| |
Collapse
|